TFF PHARMACEUTICALS, INC. Net Change in Cash
TFF PHARMACEUTICALS, INC. reported Net Change in Cash of -$2.87 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-20.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2024-11-20
- TFF PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$2.27M.
- TFF PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$4.40M.
- TFF PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$7.38M, a 132.44% decline year-over-year.
- TFF PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was $22.75M.
- TFF PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$11.13M.
- TFF PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$17.18M.
- TFF PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was -$1.51M, a 120.90% decline from fiscal 2020.
- TFF PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was $7.21M, a 59.59% decline from fiscal 2019.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$2.87M 10-Q · filed 2024-11-20 | |||
| 2024-06-30 | -$1.09M 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | -$2.27M 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | -$11.13M 10-K · filed 2024-03-28 | |||
| 2023-09-30 | -$6.89M 10-Q · filed 2024-11-20 | |||
| 2023-06-30 | -$8.95M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$4.40M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$17.18M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$20.65M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$12.90M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$7.38M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$1.51M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $9.41M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $16.77M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $22.75M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $7.21M 10-K · filed 2022-03-24 | |||
| 2020-09-30 | $13.52M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$6.17M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$2.36M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $17.83M 10-K · filed 2021-03-10 | |||
| 2019-09-30 | $288.90K 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $3.37M 10-Q · filed 2020-08-13 |